AP2014008002A0 - Anti-baff-anti-IL-17 bispecific antibodies - Google Patents

Anti-baff-anti-IL-17 bispecific antibodies

Info

Publication number: AP2014008002A0
Authority: AP; ARIPO
Prior art keywords: baff; bispecific antibodies; bispecific; antibodies
Prior art date: 2012-04-20

Application number

AP2014008002A

Other languages

English (en)

Inventor

Robert Jan Benschop

Barrett Allan

Jirong Lu

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-20

Filing date

2013-04-16

Publication date

2014-10-31

2013-04-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-10-31 Publication of AP2014008002A0 publication Critical patent/AP2014008002A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AP2014008002A 2012-04-20 2013-04-16 Anti-baff-anti-IL-17 bispecific antibodies AP2014008002A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261636302P	2012-04-20	2012-04-20
US201361768747P	2013-02-25	2013-02-25
PCT/US2013/036677 WO2013158577A1 (en)	2012-04-20	2013-04-16	Anti-baff-anti-il-17 bispecific antibodies

Publications (1)

Publication Number	Publication Date
AP2014008002A0 true AP2014008002A0 (en)	2014-10-31

Family

ID=48539373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2014008002A AP2014008002A0 (en)	2012-04-20	2013-04-16	Anti-baff-anti-IL-17 bispecific antibodies

Country Status (39)

Country	Link
US (2)	US9359448B2 (xx)
EP (2)	EP2838920B1 (xx)
JP (1)	JP6216772B2 (xx)
KR (1)	KR101673735B1 (xx)
CN (1)	CN104220455B (xx)
AP (1)	AP2014008002A0 (xx)
AR (1)	AR090626A1 (xx)
AU (1)	AU2013249546B2 (xx)
BR (1)	BR112014025649A2 (xx)
CA (1)	CA2869148C (xx)
CL (1)	CL2014002616A1 (xx)
CO (1)	CO7160039A2 (xx)
CR (1)	CR20140466A (xx)
CY (1)	CY1118824T1 (xx)
DK (1)	DK2838920T3 (xx)
DO (1)	DOP2014000234A (xx)
EA (1)	EA029185B1 (xx)
EC (1)	ECSP14023405A (xx)
ES (2)	ES2789474T3 (xx)
GT (1)	GT201400217A (xx)
HR (1)	HRP20170468T1 (xx)
HU (1)	HUE032153T2 (xx)
IL (1)	IL234965B (xx)
IN (1)	IN2014MN01876A (xx)
LT (1)	LT2838920T (xx)
ME (1)	ME02596B (xx)
MX (1)	MX367460B (xx)
MY (1)	MY173282A (xx)
NZ (1)	NZ630865A (xx)
PE (1)	PE20142147A1 (xx)
PH (1)	PH12014502333A1 (xx)
PL (1)	PL2838920T3 (xx)
PT (1)	PT2838920T (xx)
RS (1)	RS55729B1 (xx)
SG (1)	SG11201406726PA (xx)
SI (1)	SI2838920T1 (xx)
TW (1)	TWI585103B (xx)
WO (1)	WO2013158577A1 (xx)
ZA (1)	ZA201407272B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG185354A1 (en)	2010-05-20	2012-12-28	Ablynx Nv	Biological materials related to her3
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) *	2012-04-20	2014-11-26	Lilly Co Eli	Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) *	2013-03-08	2014-12-01	Lilly Co Eli	抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
WO2015077071A1 (en)	2013-11-19	2015-05-28	Regeneron Pharmaceuticals, Inc.	Non-human animals having a humanized b-cell activating factor gene
BR112016014731A2 (pt)	2014-01-31	2017-09-19	Boehringer Ingelheim Int	Anticorpos anti-baff
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
KR102644875B1 (ko) *	2015-07-23	2024-03-06	베링거잉겔하임인터내쇼날유한회사	Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도
CN105061596B (zh) *	2015-08-05	2019-01-29	江苏诺迈博生物医药科技有限公司	人b淋巴细胞刺激因子的单克隆抗体及其应用
WO2019136311A2 (en) *	2018-01-05	2019-07-11	Biograph 55, Inc.	Compositions and methods for cancer immunotherapy
WO2022258045A1 (zh) *	2021-06-11	2022-12-15	山东先声生物制药有限公司	抗人il-17抗体和taci的双功能融合蛋白分子
KR20250127162A (ko) *	2022-12-28	2025-08-26	쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드	항-baff 항체를 포함하는 이중특이적 결합 단백질 및 이의 용도
TW202440636A (zh)	2023-03-21	2024-10-16	美商傳記５５有限公司	Ｃｄ１９／ｃｄ３８多特異性抗體
WO2025109206A1 (en)	2023-11-22	2025-05-30	Mabylon Ag	Multispecific anti-allergen antibodies and uses thereof
WO2025108551A1 (en)	2023-11-23	2025-05-30	Mabylon Ag	Multispecific anti-allergen antibodies and uses thereof
WO2025222167A1 (en) *	2024-04-19	2025-10-23	Zb17 Llc	Methods of treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995009917A1 (en)	1993-10-07	1995-04-13	The Regents Of The University Of California	Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) *	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
RU2515108C2 (ru) *	2005-08-19	2014-05-10	Эббви Инк	Иммуноглобулин с двойными вариабельными доменами и его применения
EP1963368B3 (en)	2005-12-13	2020-06-10	Eli Lilly And Company	Anti-il-17 antibodies
WO2011141823A2 (en) *	2010-05-14	2011-11-17	Orega Biotech	Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
AR090626A1 (es) *	2012-04-20	2014-11-26	Lilly Co Eli	Anticuerpos anti-baff-anti-il-17 biespecificos

2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/es active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/zh not_active IP Right Cessation
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/lt unknown
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 PL PL13726321T patent/PL2838920T3/pl unknown
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/ja active Active
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/me unknown
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 ES ES17153380T patent/ES2789474T3/es active Active
- 2013-04-16 EA EA201491622A patent/EA029185B1/ru not_active IP Right Cessation
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/es active Active
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 RS RS20170160A patent/RS55729B1/sr unknown
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/zh active Active
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en not_active Ceased
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/es active IP Right Grant
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/ko not_active Expired - Fee Related
- 2013-04-16 SI SI201330522A patent/SI2838920T1/sl unknown
- 2013-04-16 MX MX2014012692A patent/MX367460B/es active IP Right Grant
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 HR HRP20170468TT patent/HRP20170468T1/hr unknown
- 2013-04-16 PT PT137263216T patent/PT2838920T/pt unknown
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/xx unknown
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/pt not_active Application Discontinuation
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/es unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/es unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/es unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/es unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/es unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/es unknown
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
2017
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/el unknown

Also Published As

Publication number	Publication date
CA2869148C (en)	2017-06-20
PT2838920T (pt)	2017-05-03
CN104220455A (zh)	2014-12-17
KR20140135830A (ko)	2014-11-26
BR112014025649A2 (pt)	2017-07-04
AU2013249546B2 (en)	2017-10-26
EA201491622A1 (ru)	2015-01-30
CN104220455B (zh)	2017-04-26
KR101673735B1 (ko)	2016-11-07
CO7160039A2 (es)	2015-01-15
EP2838920B1 (en)	2017-02-01
IL234965B (en)	2018-04-30
EP2838920A1 (en)	2015-02-25
US20130280256A1 (en)	2013-10-24
PL2838920T3 (pl)	2017-07-31
ES2789474T3 (es)	2020-10-26
IN2014MN01876A (xx)	2015-07-03
DOP2014000234A (es)	2014-11-30
LT2838920T (lt)	2017-05-25
US20160251430A1 (en)	2016-09-01
JP6216772B2 (ja)	2017-10-18
TW201402607A (zh)	2014-01-16
NZ630865A (en)	2016-02-26
HUE032153T2 (en)	2017-09-28
HRP20170468T1 (hr)	2017-06-02
US9708402B2 (en)	2017-07-18
JP2015514423A (ja)	2015-05-21
PH12014502333B1 (en)	2014-12-22
MX2014012692A (es)	2015-01-22
PE20142147A1 (es)	2014-12-13
AR090626A1 (es)	2014-11-26
SG11201406726PA (en)	2014-11-27
TWI585103B (zh)	2017-06-01
WO2013158577A1 (en)	2013-10-24
HK1201862A1 (en)	2015-09-11
GT201400217A (es)	2015-06-02
SI2838920T1 (sl)	2017-03-31
ECSP14023405A (es)	2015-09-30
DK2838920T3 (en)	2017-04-18
CA2869148A1 (en)	2013-10-24
ES2621917T3 (es)	2017-07-05
CL2014002616A1 (es)	2015-01-30
MX367460B (es)	2019-08-22
EP3192809A1 (en)	2017-07-19
PH12014502333A1 (en)	2014-12-22
AU2013249546A1 (en)	2014-09-25
EA029185B1 (ru)	2018-02-28
ME02596B (me)	2017-06-20
RS55729B1 (sr)	2017-07-31
MY173282A (en)	2020-01-10
CY1118824T1 (el)	2018-01-10
CR20140466A (es)	2014-11-13
US9359448B2 (en)	2016-06-07
EP3192809B1 (en)	2020-04-15
ZA201407272B (en)	2016-11-30

Publication	Publication Date	Title
IL264558A (en)	2019-02-28	Anti–il–23p19 antibodies
ZA201407509B (en)	2016-02-24	Anti-fcrn antibodies
ZA201407897B (en)	2016-05-25	Protease-regulated antibodies
ZA201407272B (en)	2016-11-30	Anti-baff-anti-il-17 bispecific antibodies
IL234102A0 (en)	2014-09-30	Bispecific igg4 antibodies are aligned symmetrically to the sequence
ZA201409358B (en)	2015-12-23	Anti-siglec- 15 antibodies
ZA201407316B (en)	2015-12-23	Anti-fgfr2 antibody
AP2015008709A0 (en)	2015-09-30	Anti-tnf-anti-il-17 bispecific antibodies
SG11201504765VA (en)	2015-07-30	Anti-h7cr antibodies
ZA201407079B (en)	2016-02-24	Cdr-modified anti-siglec-15 antibody
GB201220242D0 (en)	2012-12-26	Antibody
EP2804876A4 (en)	2016-02-24	NEW ANTIBODIES
EP2811018A4 (en)	2015-05-13	ANTI-BODY ANTI-sAPPß
IL235188A0 (en)	2014-12-31	Antibodies against c-pdgf
GB201209584D0 (en)	2012-07-11	Modified antibodies